Budesonide aerosolised - Pari Pharma

Drug Profile

Budesonide aerosolised - Pari Pharma

Alternative Names: Buparid; Buparid/PARI Sinus

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator PARI Pharma GmbH
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rhinosinusitis

Most Recent Events

  • 05 Oct 2016 Budesonide is still in phase III trials for Rhinosinusitis in Germany (Intranasal, Aerosol) (NCT01955980)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 Pari Pharma initiates enrolment in a phase III trial for Rhinosinusitis in Germany (NCT01955980)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top